Lilly's Decision to Pursue a New Drug Is Confusing

At both week 12 and week 24, the barisitinib outperformed significantly so cyclophosphamide. Now the fault here of course is that they're using pro-Nuria as an endpoint. And there are many other endpoints that could be used,. But it turns out some of their secondary endpoints also look good here. The next three are drugs that are in development and in phase two. OPO137 teletacisets. ABBV599 high dose. We pass it in the balloon or the combination of the patter sitting in plus L's butenib. VAY 737. This is an anti-bath receptor monoclonal antibody poster number